For a decade, the promise of a wearable that could silently watch over one of humanity's most prevalent and underdiagnosed diseases has remained just out of reach. Now, a pendant-sized device called Isaac — which reads the chemical whispers in human breath to detect signs of diabetes — has entered FDA clinical trials at Indiana University, offering the most credible path yet toward non-invasive glucose monitoring. With over ten percent of adults living with diabetes and nearly half unaware of it, the distance between a laboratory trial and a wrist-worn device has rarely carried such weight.
9to5Mac
· Jan 08, 2026
· health
· 2 min read
High
Sourcing: Characterized
Apple Watch glucose monitoring edges closer as non-invasive breath-test tech enters FDA trials
Millions die annually from diabetes; early non-invasive detection could prevent deaths and improve outcomes for undiagnosed patients.
◉
Health & Medicine
8293 related articles
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% match
Global health agencies race to contain Ebola outbreak as vaccine fundi…
Devdiscourse · 99% match
CDC warns Congo Ebola outbreak could exceed West Africa crisis without…
Devdiscourse · 99% match
Two Cancer Drugs Show Promise Reversing Alzheimer's Damage in Mice
ScienceAlert · 99% match
Kidney drug finerenone shows promise for millions beyond diabetes pati…
ScienceDaily · 99% match
Related Coverage
7NEWS · Aug 23
Model's Foot Cut Led to Heart Surgery, Baby Loss—Now Advocating for Better Diagnostics
Australian model Leah Ramsey lost her baby after a small foot cut triggered a rare heart infection that was repeatedly m…
Informanté · Aug 23 South Africa Shares FMD Vaccines as Region Strengthens Disease ControlsSouth Africa reports its largest-ever FMD outbreak is coming under control through accelerated vaccination and regional …
Al Jazeera · Aug 23 Solar telemedicine kiosks expand healthcare access across rural ChadSolar-powered telemedicine kiosks in rural Chad enable remote doctor consultations at a fraction of traditional travel c…
Inquirer.net · Aug 23 Prince Harry returns to UK amid family rifts, seeking reconciliation with monarchyPrince Harry and Meghan Markle are relocating back to Britain after six years in California, potentially signaling recon…
Bias & Framing
⚖
Article presents promising glucose monitoring technology with pro-innovation framing, minimal skepticism about feasibility claims, and Apple-centric perspective on health tech advancement.
Bias Direction
center-right
Confidence
HIGH
Technology optimism framing: positions non-invasive glucose monitoring as inevitable progress toward Apple Watch integration, emphasizing potential life-saving benefits while downplaying technical hurdles and timeline uncertainty.
holy grail in health tech
potentially save a huge number of lives
breakthrough
edges closer
most promising route
potentially paving the way
Skeptical medical experts questioning feasibility or accuracy claims
Competing non-Apple health tech companies or alternative solutions
Regulatory experts discussing FDA approval challenges or timeline realism
Patient perspectives on existing monitoring solutions
Cost and accessibility concerns for non-Apple Watch users
Historical context of failed Apple health feature launches
Geopolitical Impact
🌎
This is a technology/health article, not a geopolitical matter. No international implications or power dynamics between nations are present.
Escalation Risk
low
Confidence
HIGH
Economic Lens
📈
Non-invasive breath-based glucose monitoring technology advancing through FDA trials could enable Apple Watch integration, potentially disrupting the $30B+ diabetes management market and expanding preventive health screening.
Market Signal
bullish
Confidence
MED
Medical devices and diagnostics
Consumer electronics (Apple/wearables)
Healthcare technology
Pharmaceutical (diabetes management)
Insurance and preventive care
Consumers with diabetes or at-risk populations gain non-invasive, continuous glucose monitoring integrated into existing wearables, reducing friction for early diagnosis and daily management. Potential cost reduction if FDA-approved device becomes widely accessible. Millions of undiagnosed diabetics could benefit from passive screening.
FDA approval pathway will be critical; successful trials could accelerate regulatory frameworks for non-invasive biomarker detection in wearables. Insurance coverage decisions will influence adoption rates. Privacy/data security regulations for continuous health monitoring will require attention. Public health agencies may promote screening programs leveraging ubiquitous wearable technology.